Three biotech stocks on the cutting edge of medicine

Investors are only now recognising the vast potential of biotech stocks. Here. Professional investor Dr Daniel Koller of BB Biotech AG picks three of his favourites.

Each week, aprofessional investor tells us where he'd put his money. This week: Dr Daniel Koller of BB Biotech AG highlights three favourites.

Health is the key to a long and happy life. The biotechnology sector plays a crucial role in providing people with the means to recover from disease and remain as robust as possible and investors are only beginning to recognise its vast potential. The sector has encountered some short-term turbulence, however. The Nasdaq Biotechnology index (NBI) enjoyed a stellar first quarter of 2019 fuelled by mergers-and-acquisitions (M&A) activity, but it has since declined by 2%.

The political backdrop has unnerved investors. In the US the pressure to lower drug prices is growing. Healthcare costs and the cost of medicine have taken centre-stage in the Democratic Party's presidential primaries. The Trump administration recently retreated from a plan to lower prescription-drug charges, but has also threatened to use international drug prices to establish ceilings on what the health system will pay for various treatments.

An auspicious outlook

The key innovators in the sector

Ionis Pharmaceuticals (Nasdaq: IONS)

Incyte (Nasdaq: INCY) primarily focuses on oncology (cancer treatment). The company has assembled a renowned team of drug discovery and development scientists focused on targeted oncology, which enables anti-tumour drugs to attack the right cells. Its main drug, Jakafi, treats rare types of blood cancer. Another intriguing outfit is Neurocrine Biosciences (Nasdaq: NBIX), which focuses on neurological and hormone-related disorders. Neurocrine has successfully launched the drugs Ingrezza for the treatment of mental-health disorders and Orilissa for gynaecological problems.

Recommended

A family-run investment trust to buy and lock away
Investment trusts

A family-run investment trust to buy and lock away

Menhaden Resource Efficiency made a slow start, but progress is encouraging. Buy before the discount closes, says Max King.
16 May 2022
Why investors should consider adding Glencore to their portfolios
Share tips

Why investors should consider adding Glencore to their portfolios

Commodities giant Glencore is well placed to capitalise on rising commodity prices and supply chain disruption, says Rupert Hargreaves. Here’s why you…
13 May 2022
Share tips of the week – 13 May
Share tips

Share tips of the week – 13 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 May 2022
How to invest in litigation finance – and get returns from bankrolling legal disputes
Share tips

How to invest in litigation finance – and get returns from bankrolling legal disputes

Lawsuits are a trillion-dollar business and litigation-finance firms play a key role in funding claims. The accounting can be complex, but there are o…
12 May 2022

Most Popular

High inflation will fade – here’s why
Inflation

High inflation will fade – here’s why

Many people expect high inflation to persist for a long time. But that might not be true, says Max King. Inflation may fall faster than expected – and…
13 May 2022
Cryptocurrencies are crashing – so how low will bitcoin go?
Bitcoin & crypto

Cryptocurrencies are crashing – so how low will bitcoin go?

The entire cryptocurrency sector is crashing, with bitcoin now well below $30,000. This is big, says Dominic Frisby. So just how low could bitcoin go?
12 May 2022
What the Ukraine crisis might mean for ESG investing
Advertisement Feature

What the Ukraine crisis might mean for ESG investing

The Ukraine crisis has brought many of the issues around ESG investing into sharper focus. Where does the sector go from here?
3 May 2022